$10,000 invested in this ASX healthcare share a year ago is now worth $36,500

MotleyFool03-26 11:53

ASX healthcare share Starpharma Holdings Ltd (ASX: SPL) has rocketed 365% over the past 12 months. Had you put $10,000 into this ASX small-cap share in March 2025, your holdings would be worth $36,500...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622188031?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 11:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622188031","market":"nz","top_or_hot":-1,"title":"$10,000 invested in this ASX healthcare share a year ago is now worth $36,500","media":"MotleyFool","content":"<div>\n<p>ASX healthcare share Starpharma Holdings Ltd (ASX: SPL) has rocketed 365% over the past 12 months.\nHad you put $10,000 into this ASX small-cap share in March 2025, your holdings would be worth $36,500...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/26/10000-invested-in-this-asx-healthcare-share-a-year-ago-is-now-worth-36500/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>$10,000 invested in this ASX healthcare share a year ago is now worth $36,500</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n$10,000 invested in this ASX healthcare share a year ago is now worth $36,500\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-26 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2026/03/26/10000-invested-in-this-asx-healthcare-share-a-year-ago-is-now-worth-36500/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ASX healthcare share Starpharma Holdings Ltd (ASX: SPL) has rocketed 365% over the past 12 months.\nHad you put $10,000 into this ASX small-cap share in March 2025, your holdings would be worth $36,500...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/26/10000-invested-in-this-asx-healthcare-share-a-year-ago-is-now-worth-36500/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RAD.AU","symbol_name":"RADIOPHARM THERANOSTICS LTD","start_time":0,"source_url":"https://www.fool.com.au/2026/03/26/10000-invested-in-this-asx-healthcare-share-a-year-ago-is-now-worth-36500/","article_id":"2622188031","we_media_id":null,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/26/10000-invested-in-this-asx-healthcare-share-a-year-ago-is-now-worth-36500/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622188031","pubTimestamp":1774497205,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"ASXhealthcare share Starpharma Holdings Ltd  has rocketed 365% over the past 12 months.Had you put $10,000 into this ASXsmall-capshare in March 2025, your holdings would be worth $36,500 today.These nanoscale molecules make medicines more effective in the body.Starpharma licenses its drug delivery technology to large pharma, and also develops its own anti-infection products.This ASX healthcare share is trading at 47 cents on Thursday, up 1.1%.What's behind the dramatic 365% share price rise?In September, the ASX healthcare share rose by more than 100% after the company announced two new partnerships.Starpharma signed a research and option agreement with Radiopharm Theranostics Ltd that made it eligible to receive a $500,000 option fee, a $2 million upfront payment, and up to $89 million in success-based payments and royalties on net sales.Is it too late to buy this rising ASX healthcare share?ASX biotech shares are notoriously risky and unsuitable for investors with a low risk toleranc","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"RAD.AU":"RADIOPHARM THERANOSTICS LTD","SPL.AU":"STARPHARMA HOLDINGS LTD","BK7067":"生物科技","VHT":"Vanguard Health Care ETF","BK7508":"医药生物股","IXJ":"全球医疗业ETF-iShares","BK7501":"新冠治疗股","BK7096":"制药","BK4550":"红杉资本持仓","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"一年前投资于ASX healthcare股票的10,000美元现在价值36,500美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPL.AU":1,"VHT":1.5,"RAD.AU":1,"IXJ":1.5},"content_text":"ASX healthcare share Starpharma Holdings Ltd (ASX: SPL) has rocketed 365% over the past 12 months.\nHad you put $10,000 into this ASX small-cap share in March 2025, your holdings would be worth $36,500 today. \nStarpharma is an Australian biotech that develops drug delivery systems using proprietary polymers called dendrimers.\nThese nanoscale molecules make medicines more effective in the body.\nStarpharma licenses its drug delivery technology to large pharma, and also develops its own anti-infection products.\nThis ASX healthcare share is trading at 47 cents on Thursday, up 1.1%.\nImage source: Getty Images\nWhat's behind the dramatic 365% share price rise? \nThe bulk of Starpharma's rise over the past 12 months occurred between late September and February. \nIn September, the ASX healthcare share rose by more than 100% after the company announced two new partnerships. \nStarpharma announced a new deal with drug company Genentech, which it has worked with for more than three years.\nThe companies will develop cancer treatments using Starpharma's proprietary DEP drug delivery technology.\nUnder the deal, Starpharma got an upfront payment of US$5.5 million. \nIt is also eligible to receive up to US$564 million in success-based payments over time. \nStarpharma granted Genentech an exclusive global licence to commercialise any products developed via the collaboration.\nStarpharma CEO Cheryl Maley said:\n\nA key strategic priority for Starpharma is to build new, high-impact partnerships that unlock the full potential of our DEP platform. \nBy actively pursuing licensing opportunities and collaborating with leading organisations, we aim to expand market reach and enable our partners to deliver significantly improved therapies to patients worldwide.\n\nThe ASX healthcare share surged again when the company announced its first radiopharmaceutical partnership. \nStarpharma signed a research and option agreement with Radiopharm Theranostics Ltd (ASX: RAD) that made it eligible to receive a $500,000 option fee, a $2 million upfront payment, and up to $89 million in success-based payments and royalties on net sales.\nMaley called the deal a key milestone, and said radiopharmaceuticals was a strong area of focus for Starpharma. \nIn its 1H FY26 report in February, Starpharma reported a 474% increase in revenue to $10.8 million for the six months to 31 December. \nThe half-year profit was $1,367,000, up from a loss of $5,392,000 in 1H FY24. \nIs it too late to buy this rising ASX healthcare share? \nASX biotech shares are notoriously risky and unsuitable for investors with a low risk tolerance. \nPAC Partners gives this one a buy rating with a \"high risk\" 12-month price target of 80 cents to $1.\nPAC Partners forecasts growth in partnerships as well as over-the-counter revenue over the next four years.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622188031","isCrawlerRequest":true}